In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients

M. Caggana, H. L. Liber, P. M. Mauch, C. N. Coleman, K. T. Kelsey

Research output: Contribution to journalArticle

Abstract

While current medical therapies for Hodgkin's disease are usually quite effective, it has become increasingly clear that some of the therapies utilized carry an inherent risk for the induction of secondary malignancies. In order to examine the cellular and genetic responses to therapy for Hodgkin's disease among individuals, we have determined the mutant frequency of T-lymphocytes in 3 cohorts of patients (N = 86) and in controls (N = 71) using a T-cell cloning assay selecting for 6-thioguanine resistance. The Hodgkin's disease cohorts studied include 1) new and untreated, 2) radiotherapy, and 3) combined modality therapy patients. Additionally, two patients receiving chemotherapy alone were studied. In untreated patients, 3 of 18 (17%) mutant frequencies were above the upper 95% confidence limit for mutant frequency in controls (12.6 x 10-6). After therapy, 14 out of 45 (31%) of those treated with X-rays only and 10 of 23 (44%) patients treated with both X-rays and chemotherapy had mutant frequencies greater than 12.6 x 10-6. Overall, the results indicated that the individual response to Hodgkin's disease therapy was a heterogeneous one with a sub-population of persons having elevated mutant frequencies even many years after their last treatment. The larger frequency of elevated MFs in those patients who received intensive therapy (chemotherapy and radiotherapy) is consistent with their increased risk for second cancer induction.

Original languageEnglish (US)
Pages (from-to)6-13
Number of pages8
JournalEnvironmental and Molecular Mutagenesis
Volume18
Issue number1
StatePublished - 1991
Externally publishedYes

Fingerprint

Lymphocytes
Hodgkin Disease
Chemotherapy
mutation
Mutation
T-cells
chemotherapy
Radiotherapy
Thioguanine
X rays
Cloning
Drug Therapy
Therapeutics
Assays
X-Rays
T-Lymphocytes
Combined Modality Therapy
Second Primary Neoplasms
therapy
subpopulation

Keywords

  • Hodgkin's lymphoma
  • hprt mutation
  • T-lymphocytes

ASJC Scopus subject areas

  • Environmental Science(all)
  • Environmental Chemistry
  • Genetics
  • Genetics(clinical)
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Caggana, M., Liber, H. L., Mauch, P. M., Coleman, C. N., & Kelsey, K. T. (1991). In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients. Environmental and Molecular Mutagenesis, 18(1), 6-13.

In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients. / Caggana, M.; Liber, H. L.; Mauch, P. M.; Coleman, C. N.; Kelsey, K. T.

In: Environmental and Molecular Mutagenesis, Vol. 18, No. 1, 1991, p. 6-13.

Research output: Contribution to journalArticle

Caggana, M, Liber, HL, Mauch, PM, Coleman, CN & Kelsey, KT 1991, 'In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients', Environmental and Molecular Mutagenesis, vol. 18, no. 1, pp. 6-13.
Caggana, M. ; Liber, H. L. ; Mauch, P. M. ; Coleman, C. N. ; Kelsey, K. T. / In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients. In: Environmental and Molecular Mutagenesis. 1991 ; Vol. 18, No. 1. pp. 6-13.
@article{7141f9ba03bb49c6b4507444fb0f2850,
title = "In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients",
abstract = "While current medical therapies for Hodgkin's disease are usually quite effective, it has become increasingly clear that some of the therapies utilized carry an inherent risk for the induction of secondary malignancies. In order to examine the cellular and genetic responses to therapy for Hodgkin's disease among individuals, we have determined the mutant frequency of T-lymphocytes in 3 cohorts of patients (N = 86) and in controls (N = 71) using a T-cell cloning assay selecting for 6-thioguanine resistance. The Hodgkin's disease cohorts studied include 1) new and untreated, 2) radiotherapy, and 3) combined modality therapy patients. Additionally, two patients receiving chemotherapy alone were studied. In untreated patients, 3 of 18 (17{\%}) mutant frequencies were above the upper 95{\%} confidence limit for mutant frequency in controls (12.6 x 10-6). After therapy, 14 out of 45 (31{\%}) of those treated with X-rays only and 10 of 23 (44{\%}) patients treated with both X-rays and chemotherapy had mutant frequencies greater than 12.6 x 10-6. Overall, the results indicated that the individual response to Hodgkin's disease therapy was a heterogeneous one with a sub-population of persons having elevated mutant frequencies even many years after their last treatment. The larger frequency of elevated MFs in those patients who received intensive therapy (chemotherapy and radiotherapy) is consistent with their increased risk for second cancer induction.",
keywords = "Hodgkin's lymphoma, hprt mutation, T-lymphocytes",
author = "M. Caggana and Liber, {H. L.} and Mauch, {P. M.} and Coleman, {C. N.} and Kelsey, {K. T.}",
year = "1991",
language = "English (US)",
volume = "18",
pages = "6--13",
journal = "Environmental and Molecular Mutagenesis",
issn = "0893-6692",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients

AU - Caggana, M.

AU - Liber, H. L.

AU - Mauch, P. M.

AU - Coleman, C. N.

AU - Kelsey, K. T.

PY - 1991

Y1 - 1991

N2 - While current medical therapies for Hodgkin's disease are usually quite effective, it has become increasingly clear that some of the therapies utilized carry an inherent risk for the induction of secondary malignancies. In order to examine the cellular and genetic responses to therapy for Hodgkin's disease among individuals, we have determined the mutant frequency of T-lymphocytes in 3 cohorts of patients (N = 86) and in controls (N = 71) using a T-cell cloning assay selecting for 6-thioguanine resistance. The Hodgkin's disease cohorts studied include 1) new and untreated, 2) radiotherapy, and 3) combined modality therapy patients. Additionally, two patients receiving chemotherapy alone were studied. In untreated patients, 3 of 18 (17%) mutant frequencies were above the upper 95% confidence limit for mutant frequency in controls (12.6 x 10-6). After therapy, 14 out of 45 (31%) of those treated with X-rays only and 10 of 23 (44%) patients treated with both X-rays and chemotherapy had mutant frequencies greater than 12.6 x 10-6. Overall, the results indicated that the individual response to Hodgkin's disease therapy was a heterogeneous one with a sub-population of persons having elevated mutant frequencies even many years after their last treatment. The larger frequency of elevated MFs in those patients who received intensive therapy (chemotherapy and radiotherapy) is consistent with their increased risk for second cancer induction.

AB - While current medical therapies for Hodgkin's disease are usually quite effective, it has become increasingly clear that some of the therapies utilized carry an inherent risk for the induction of secondary malignancies. In order to examine the cellular and genetic responses to therapy for Hodgkin's disease among individuals, we have determined the mutant frequency of T-lymphocytes in 3 cohorts of patients (N = 86) and in controls (N = 71) using a T-cell cloning assay selecting for 6-thioguanine resistance. The Hodgkin's disease cohorts studied include 1) new and untreated, 2) radiotherapy, and 3) combined modality therapy patients. Additionally, two patients receiving chemotherapy alone were studied. In untreated patients, 3 of 18 (17%) mutant frequencies were above the upper 95% confidence limit for mutant frequency in controls (12.6 x 10-6). After therapy, 14 out of 45 (31%) of those treated with X-rays only and 10 of 23 (44%) patients treated with both X-rays and chemotherapy had mutant frequencies greater than 12.6 x 10-6. Overall, the results indicated that the individual response to Hodgkin's disease therapy was a heterogeneous one with a sub-population of persons having elevated mutant frequencies even many years after their last treatment. The larger frequency of elevated MFs in those patients who received intensive therapy (chemotherapy and radiotherapy) is consistent with their increased risk for second cancer induction.

KW - Hodgkin's lymphoma

KW - hprt mutation

KW - T-lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0025742688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025742688&partnerID=8YFLogxK

M3 - Article

C2 - 1713845

AN - SCOPUS:0025742688

VL - 18

SP - 6

EP - 13

JO - Environmental and Molecular Mutagenesis

JF - Environmental and Molecular Mutagenesis

SN - 0893-6692

IS - 1

ER -